Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State
- PMID: 16868498
- PMCID: PMC2925654
- DOI: 10.1097/01.qai.0000225871.87456.e7
Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State
Abstract
Prevalence studies indicate that transmission of drug-resistant HIV has been rising in the adult population, but data from the perinatally infected pediatric population are limited. In this retrospective study, we sequenced the pol region of HIV from perinatally infected infants diagnosed in New York State in 2001-2002. Analyses of drug resistance, subtype diversity, and perinatal antiretroviral exposure were conducted, and the results were compared with those from a previous study of HIV-infected infants identified in 1998-1999. Eight of 42 infants (19.1%) had provirus carrying at least 1 drug-resistance mutation, an increase of 58% over the 1998-1999 results. Mutations conferring resistance to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 7.1%, 11.9%, and 2.4% of specimens, respectively. Consistent with previous results, perinatal antiretroviral exposure was not associated with drug resistance (P = 0.70). Phylogenetic analysis indicated that 16.7% of infants were infected with a non-subtype B strain of HIV. It seems that drug-resistant and non-subtype B strains of HIV are becoming increasingly common in the perinatally infected population. Our results highlight the value of resistance testing for all HIV-infected infants upon diagnosis and the need to consider subtype diversity in diagnostic and treatment strategies.
Figures

Similar articles
-
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):148-53. doi: 10.1097/QAI.0b013e31802b920e. J Acquir Immune Defic Syndr. 2007. PMID: 17117145
-
Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades.J Infect Dis. 2001 Nov 1;184(9):1120-6. doi: 10.1086/323804. Epub 2001 Sep 20. J Infect Dis. 2001. PMID: 11598834
-
Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.Retrovirology. 2009 Sep 19;6:85. doi: 10.1186/1742-4690-6-85. Retrovirology. 2009. PMID: 19765313 Free PMC article.
-
Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance.J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):216-29. doi: 10.1097/00042560-200206010-00011. J Acquir Immune Defic Syndr. 2002. PMID: 12045685 Review.
-
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):509-12. doi: 10.1097/QAI.0b013e3181aa8a3d. J Acquir Immune Defic Syndr. 2009. PMID: 19521253 Review. No abstract available.
Cited by
-
Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island.Infect Genet Evol. 2014 Dec;28:358-66. doi: 10.1016/j.meegid.2014.03.027. Epub 2014 Apr 8. Infect Genet Evol. 2014. PMID: 24721515 Free PMC article.
-
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.Cochrane Database Syst Rev. 2014 May 22;2014(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Cochrane Database Syst Rev. 2014. PMID: 24852077 Free PMC article.
-
Pregnancy in women with perinatally acquired HIV-infection: outcomes and challenges.AIDS Care. 2011 Sep;23(9):1076-82. doi: 10.1080/09540121.2011.554643. Epub 2011 May 23. AIDS Care. 2011. PMID: 21562997 Free PMC article.
-
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.PLoS One. 2009;4(3):e4806. doi: 10.1371/journal.pone.0004806. Epub 2009 Mar 11. PLoS One. 2009. PMID: 19277127 Free PMC article.
-
Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis.EClinicalMedicine. 2024 Oct 4;77:102859. doi: 10.1016/j.eclinm.2024.102859. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39430612 Free PMC article.
References
-
- Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Feb 25, 2005. Available at: http://aidsinfo.nih.gov/guidelines/perinatal/PER_022405.pdf. - PubMed
-
- Mofenson LM. Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 serosurvey of childbearing women. Arch Pediatr Adolesc Med. 2004;158:422–425. - PubMed
-
- Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393–1401. - PubMed
-
- Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135–1141. - PubMed
-
- Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases